What is diabetes?
We’re pursuing leading, distinctive science in diabetes with the goal of developing life-changing medicines that reduce the global burden and complications of this serious disease.
Type-2 diabetes occurs when the body builds a resistance to insulin, meaning the body is unable to regulate blood glucose levels.
There is a clinical overlap between diabetes, cardiovascular disease (CVD) and renal diseases. People with type-2 diabetes are two to three times more likely to suffer from heart attacks and strokes compared to those without diabetes, and have a greater risk of chronic kidney disease, which affects more than 30 million adults in the United States alone.
We are committed to better understanding the interconnectivity of diabetes, cardiovascular and renal diseases and taking a holistic, patient-centric approach to disease management.
What we're working on
We are pursuing high-science research and early-action treatment options to support people living with diabetes.
DapaCare is a clinical programme aimed at better understanding the cardiovascular and renal profile of dapagliflozin in people with and without type-2 diabetes. The programme will enrol nearly 30,000 patients in randomised clinical trials and generate data across a spectrum of people with established cardiovascular disease, cardiovascular risk factors and renal disease, providing evidence on the effects on patient outcomes.
Early Action in Diabetes (EAiD)
EAiD is collecting and sharing better practices in policymaking from around the world. More than 35 countries now participate in the initiative, with strategies and action plans outlining how policymakers, healthcare professionals, payers and patient advocacy groups can best work together to prevent, diagnose and control diabetes. National stakeholders congregate in annual global policy forums, sharing better practices and progress reports for implementation of national plans. EAiD is built around a global vision for excellent policymaking, developed by experts from around the world, and applicable to low-, mid-and high-income countries.Read more
1. American Diabetes Association. Facts About Type 2. Accessed 17 August 2017. http://www.diabetes.org/diabetes-basics/type-2/facts-about-type-2.html.
2. World Health Organization. Media Centre. Diabetes Fact Sheet. Reviewed November 2016. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/.
3. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Available at http://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf.
4. ClinicalTrials.gov. “A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD).” Available at https://clinicaltrials.gov/ct2/show/NCT03036150.
5. ClinicalTrials.gov. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). Available at https://clinicaltrials.gov/ct2/show/NCT03036124.
Veeva ID: Z4-6509
Date of expiry: August 2018